Skip to main content

Table 5 Relation between marker (serum chromogranin A) and patient characteristics [181] (note that missing data were not indicated).

From: Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration

  Serum CgA levels, ng/mL  
  Number Median Q1 to Q3 Minimum to maximum P
Subjects      
   Controls 50 77.4 57.7 to 99.9 28.2 to 196.3  
   NSCLC patients 88 70.4 37.9 to 114.6 8.7 to 723.8 0.337
Histotype      
   Adenocarcinoma 22 59.2 35.2 to 85.6 14.8 to 151.2  
   Squamous 27 80.0 41.0 to 128.6 14.7 to 386.8  
   Large cell 10 82.1 33.7 to 124.0 11.4 to 217.9 0.465
ECOG PS      
   0 16 37.7 27.2 to 68.6 8.7 to 103.1  
   1 59 76.3 43.6 to 119.2 13.9 to 429.7  
   ≥2 13 102.8 55.8 to 259.4 32.1 to 723.8 0.0005
Stage      
   IIIB 29 44.9 29.2 to 85.6 13.9 to 259.4  
   IV 59 82.5 47.1 to 119.2 8.7 to 723.8 0.043
  1. CgA: chromogranin A; ECOG PS: Eastern Cooperative Oncology Group performance status; NSCLC: non-small cell lung cancer; Q1 to Q3: interquartile range.